RIAD ABOUJAMOUS: Open Payments
NPI 1255386058 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$499 in 31 payments from 8 companies in 2025. Trend: 2023 $529 · 2024 $1,474 · 2025 $499
Food & beverage: $499
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 5 | $182 |
| Lilly USA, LLC | 19 | $176 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $56 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| ABBVIE INC. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Abbott Laboratories | 1 | $14 |
| Novo Nordisk Inc | 1 | $13 |
Products named: Korlym, JARDIANCE, MOUNJARO, Kerendia, LINZESS, FARXIGA, FREESTYLE LIBRE 3, Ozempic.
Industry payments across TX — which companies pay providers there.
